21 December 2023
Press Release
EFPIA Japan

Kasper Bødker Mejlvang appointed new Vice Chair of EFPIA JapanTOKYO – 21 December 2023 – European Federation of Pharmaceutical Industries andAssociations Japan (EFPIA Japan) announced today that Kasper Bødker Mejlvang (Presidentand Representative Director, Novo Nordisk Pharma Ltd.) has been appointed the new Vice Chairof EFPIA Japan effective 1 January 2024, with terms until March 2025. Takahiko Iwaya (SanofiK.K.) and Takafumi Horii (AstraZeneca K.K.) remain Chair and Vice Chair, respectively.
“In the coming years, the combination of a larger, elderly population combined with a low birthrate
will put immense pressure on the Japanese healthcare system and society at large. Newsolutions are needed to ensure that patients in Japan get access to new, innovative treatments ina more efficient, flexible, and sustainable healthcare system. EFPIA Japan remains committed topartnering with other stakeholders to find these solutions”, says Kasper Bødker Mejlvang upon
the appointment.
About EFPIA Japan (http://efpia.jp/)
Established in April 2002, EFPIA Japan represents 23 R&D-based European pharmaceuticalcompanies operating in Japan. In 2022, combined sales from the member companies accounted
for roughly 31% of the pharmaceutical market in Japan. The mission of EFPIA Japan is to“Contribute to healthcare and patients in Japan through the early introduction of innovative
medicines and vaccines”. EFPIA Japan aims to strengthen dialogue with decision-makers in orderto improve Japanese healthcare for all.
About EFPIA (European Federation of Pharmaceutical Industries and Associations)(http://www.efpia.eu)
The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents thebiopharmaceutical industry operating in Europe. Through its direct membership of 37 nationalassociations, 40 leading pharmaceutical companies, and a growing number of small and mediumsized enterprises (SMEs), EFPIA’s mission is to create a collaborative environment that enables
our members to innovate, discover, develop, and deliver new therapies and vaccines for people
across Europe, as well as contribute to the European economy.
Contact:Yuko Kidoguchi
EFPIA Japan Communications Committee
AstraZeneca K.K.
Phone: 070-2260-7364
Email: yuko.kidoguchi1@astrazeneca.com

EFPIA JapanTokyo Opera City Tower, 3-20-2, Nishi Shinjuku, Shinjuku-ku, Tokyo, Japan

Kasper Bødker Mejlvang
President and Representative DirectorNovo Nordisk Pharma Ltd.

Kasper Bødker Mejlvang is Senior Vice President in Novo Nordisk A/S and wasappointed President and Representative Director of Novo Nordisk Pharma Ltd.
In Japan, September 2022.
Prior to his relocation to Japan, Kasper had 20 years of experience in Novo
Nordisk across the value chain, 18 of those in senior leadership roles. He started
his career in Global HR, then became head of Business Support in manufacturing,followed by three years as Vice President in Research & Development,
supporting a major turnaround of CMC Development.
From 2008-2019 Kasper took up several leadership positions in Manufacturing,heading up Insulin API Manufacturing (2008-2010), Product Supply Global
Support (2010-2013) and the fill-finish production site in Chartres, France (20132018), leading a large turnaround of the site and growing it to more than 1,100
FTE.
From 2019 to 2022, Kasper took the position as General Manager of commercial
operations in Novo Nordisk Denmark & Iceland. During this period sales growthincreased +20% annually.
Both in his previous and current positions, Kasper has played an active role in
the health care system, e.g. as Vice Chair of the Board of Directors of the Danish
pharmaceutical trade association (LIF), as well as his current role as Vice Chair of
the European Federation of Pharmaceutical Industries and Associations Japan(EFPIA Japan) and as member of the Board of Directors of Danish Chamber ofCommerce in Japan.
Kasper was born in 1977 and holds an MSc Management from University of Bath,UK (2002), an MSc in Psychology from University of Copenhagen, DK (2005), andan Executive MBA from IMD in Lausanne, CH (2016).

As of 12 December 2023